174 related articles for article (PubMed ID: 28404924)
1. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma.
Tong Z; Chatterjee D; Deng D; Veeranki O; Mejia A; Ajani JA; Hofstetter W; Lin S; Guha S; Kopetz S; Krishnan S; Maru D
Oncotarget; 2017 Apr; 8(17):28696-28710. PubMed ID: 28404924
[TBL] [Abstract][Full Text] [Related]
2. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.
Wu W; Bhagat TD; Yang X; Song JH; Cheng Y; Agarwal R; Abraham JM; Ibrahim S; Bartenstein M; Hussain Z; Suzuki M; Yu Y; Chen W; Eng C; Greally J; Verma A; Meltzer SJ
Gastroenterology; 2013 May; 144(5):956-966.e4. PubMed ID: 23333711
[TBL] [Abstract][Full Text] [Related]
6. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma.
Tong Z; Mejia A; Veeranki O; Verma A; Correa AM; Dokey R; Patel V; Solis LM; Mino B; Kathkuda R; Rodriguez-Canales J; Lin SH; Krishnan S; Kopetz S; Blum M; Ajani JA; Hofstetter WL; Maru DM
Ther Adv Med Oncol; 2019; 11():1758835919864850. PubMed ID: 31384313
[TBL] [Abstract][Full Text] [Related]
7. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis.
Matsuzaki J; Suzuki H; Tsugawa H; Watanabe M; Hossain S; Arai E; Saito Y; Sekine S; Akaike T; Kanai Y; Mukaisho K; Auwerx J; Hibi T
Gastroenterology; 2013 Dec; 145(6):1300-11. PubMed ID: 23933602
[TBL] [Abstract][Full Text] [Related]
8. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.
Veeranki OL; Tong Z; Dokey R; Mejia A; Zhang J; Qiao Y; Singh PK; Katkhuda R; Mino B; Tailor R; Canales JR; Bassett R; Ajani J; Wu JY; Kopetz S; Blum M; Hofstetter W; Tetzlaff M; Krishnan S; Lin SH; Maru D
Oncotarget; 2019 Jul; 10(45):4703-4718. PubMed ID: 31384397
[TBL] [Abstract][Full Text] [Related]
9. Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
Zhang T; Wang Q; Ma WY; Wang K; Chang X; Johnson ML; Bai R; Bode AM; Foster NR; Falk GW; Limburg PJ; Iyer PG; Dong Z
EBioMedicine; 2019 Nov; 49():145-156. PubMed ID: 31707149
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9.
Jia Q; Hu Z; Song N; Mao W
Cardiovasc Drugs Ther; 2023 Jun; 37(3):449-460. PubMed ID: 35088192
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
Honoki K; Yoshitani K; Tsujiuchi T; Mori T; Tsutsumi M; Morishita T; Takakura Y; Mii Y
Oncol Rep; 2004 May; 11(5):1025-30. PubMed ID: 15069542
[TBL] [Abstract][Full Text] [Related]
13. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling.
Yu Z; Du J; Zhao Y; Gao Y; Li Y; Zhao K; Lu N
Cancer Lett; 2021 Feb; 498():31-41. PubMed ID: 33129955
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
15. Bile acid-induced "Minority MOMP" promotes esophageal carcinogenesis while maintaining apoptotic resistance via Mcl-1.
Xu Y; Surman DR; Diggs L; Xi S; Gao S; Gurusamy D; McLoughlin K; Drake J; Feingold P; Brown K; Wangsa D; Wangsa D; Zhang X; Ried T; Davis JL; Hernandez J; Hoang CD; Souza RF; Schrump DS; Taylor Ripley R
Oncogene; 2020 Jan; 39(4):877-890. PubMed ID: 31570787
[TBL] [Abstract][Full Text] [Related]
16. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Xu J; Xu S; Fang Y; Chen T; Xie X; Lu W
IUBMB Life; 2019 Mar; 71(3):347-356. PubMed ID: 30536701
[TBL] [Abstract][Full Text] [Related]
18. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models.
Pinto N; Prokopec SD; Ghasemi F; Meens J; Ruicci KM; Khan IM; Mundi N; Patel K; Han MW; Yoo J; Fung K; MacNeil D; Mymryk JS; Datti A; Barrett JW; Boutros PC; Ailles L; Nichols AC
PLoS One; 2020; 15(9):e0239315. PubMed ID: 32970704
[TBL] [Abstract][Full Text] [Related]
20. Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Halpern AL; Kohtz PD; White AM; Houk AK; Rehring JF; Hanson L; McCarter MD; Joshi M; Meng X; Fullerton DA; Weyant MJ
Dig Dis Sci; 2021 Mar; 66(3):784-795. PubMed ID: 32277371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
